Browse CDK9

Summary
SymbolCDK9
Namecyclin-dependent kinase 9
Aliases PITALRE; C-2k; TAK; CDC2L4; cyclin-dependent kinase 9 (CDC2-related kinase); CTK1; cell division cycle 2-lik ......
Chromosomal Location9q34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Nucleus, PML body. Note=Accumulates on chromatin in response to replication stress. Complexed with CCNT1 in nuclear speckles, but uncomplexed form in the cytoplasm. The translocation from nucleus to cytoplasm is XPO1/CRM1-dependent. Associates with PML body when acetylated.
Domain PF00069 Protein kinase domain
Function

Protein kinase involved in the regulation of transcription. Member of the cyclin-dependent kinase pair (CDK9/cyclin-T) complex, also called positive transcription elongation factor b (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNAP II) POLR2A, SUPT5H and RDBP. This complex is inactive when in the 7SK snRNP complex form. Phosphorylates EP300, MYOD1, RPB1/POLR2A and AR, and the negative elongation factors DSIF and NELF. Regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors (e.g. TNF-inducible RELA/p65 activation and IL-6-inducible STAT3 signaling). Promotes RNA synthesis in genetic programs for cell growth, differentiation and viral pathogenesis. P-TEFb is also involved in cotranscriptional histone modification, mRNA processing and mRNA export. Modulates a complex network of chromatin modifications including histone H2B monoubiquitination (H2Bub1), H3 lysine 4 trimethylation (H3K4me3) and H3K36me3; integrates phosphorylation during transcription with chromatin modifications to control co-transcriptional histone mRNA processing. The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro. Replication stress response protein; the CDK9/cyclin-K complex is required for genome integrity maintenance, by promoting cell cycle recovery from replication arrest and limiting single-stranded DNA amount in response to replication stress, thus reducing the breakdown of stalled replication forks and avoiding DNA damage. In addition, probable function in DNA repair of isoform 2 via interaction with KU70/XRCC6. Promotes cardiac myocyte enlargement. RPB1/POLR2A phosphorylation on 'Ser-2' in CTD activates transcription. AR phosphorylation modulates AR transcription factor promoter selectivity and cell growth. DSIF and NELF phosphorylation promotes transcription by inhibiting their negative effect. The phosphorylation of MYOD1 enhances its transcriptional activity and thus promotes muscle differentiation.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0003300 cardiac muscle hypertrophy
GO:0006260 DNA replication
GO:0006261 DNA-dependent DNA replication
GO:0006282 regulation of DNA repair
GO:0006352 DNA-templated transcription, initiation
GO:0006354 DNA-templated transcription, elongation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0006378 mRNA polyadenylation
GO:0006397 mRNA processing
GO:0007050 cell cycle arrest
GO:0009301 snRNA transcription
GO:0010611 regulation of cardiac muscle hypertrophy
GO:0010613 positive regulation of cardiac muscle hypertrophy
GO:0010948 negative regulation of cell cycle process
GO:0014742 positive regulation of muscle hypertrophy
GO:0014743 regulation of muscle hypertrophy
GO:0014896 muscle hypertrophy
GO:0014897 striated muscle hypertrophy
GO:0016073 snRNA metabolic process
GO:0016570 histone modification
GO:0016572 histone phosphorylation
GO:0016574 histone ubiquitination
GO:0019058 viral life cycle
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0031056 regulation of histone modification
GO:0031058 positive regulation of histone modification
GO:0031123 RNA 3'-end processing
GO:0031124 mRNA 3'-end processing
GO:0031297 replication fork processing
GO:0031396 regulation of protein ubiquitination
GO:0031398 positive regulation of protein ubiquitination
GO:0031440 regulation of mRNA 3'-end processing
GO:0031441 negative regulation of mRNA 3'-end processing
GO:0033127 regulation of histone phosphorylation
GO:0033129 positive regulation of histone phosphorylation
GO:0033182 regulation of histone ubiquitination
GO:0033184 positive regulation of histone ubiquitination
GO:0033523 histone H2B ubiquitination
GO:0042493 response to drug
GO:0042692 muscle cell differentiation
GO:0042795 snRNA transcription from RNA polymerase II promoter
GO:0043500 muscle adaptation
GO:0043502 regulation of muscle adaptation
GO:0043631 RNA polyadenylation
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044033 multi-organism metabolic process
GO:0044057 regulation of system process
GO:0045005 DNA-dependent DNA replication maintenance of fidelity
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0046782 regulation of viral transcription
GO:0048524 positive regulation of viral process
GO:0050434 positive regulation of viral transcription
GO:0050684 regulation of mRNA processing
GO:0050686 negative regulation of mRNA processing
GO:0050792 regulation of viral process
GO:0051052 regulation of DNA metabolic process
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0051147 regulation of muscle cell differentiation
GO:0071156 regulation of cell cycle arrest
GO:0071157 negative regulation of cell cycle arrest
GO:0090257 regulation of muscle system process
GO:0098781 ncRNA transcription
GO:1900363 regulation of mRNA polyadenylation
GO:1900364 negative regulation of mRNA polyadenylation
GO:1902275 regulation of chromatin organization
GO:1902415 regulation of mRNA binding
GO:1902416 positive regulation of mRNA binding
GO:1903311 regulation of mRNA metabolic process
GO:1903312 negative regulation of mRNA metabolic process
GO:1903320 regulation of protein modification by small protein conjugation or removal
GO:1903322 positive regulation of protein modification by small protein conjugation or removal
GO:1903837 regulation of mRNA 3'-UTR binding
GO:1903839 positive regulation of mRNA 3'-UTR binding
GO:1903900 regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
GO:1905214 regulation of RNA binding
GO:1905216 positive regulation of RNA binding
GO:1905269 positive regulation of chromatin organization
GO:2001020 regulation of response to DNA damage stimulus
GO:2001166 regulation of histone H2B ubiquitination
GO:2001168 positive regulation of histone H2B ubiquitination
Molecular Function GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001221 transcription cofactor binding
GO:0001223 transcription coactivator binding
GO:0003682 chromatin binding
GO:0004674 protein serine/threonine kinase activity
GO:0004693 cyclin-dependent protein serine/threonine kinase activity
GO:0008134 transcription factor binding
GO:0008353 RNA polymerase II carboxy-terminal domain kinase activity
GO:0017069 snRNA binding
GO:0097322 7SK snRNA binding
GO:0097472 cyclin-dependent protein kinase activity
Cellular Component GO:0000307 cyclin-dependent protein kinase holoenzyme complex
GO:0008023 transcription elongation factor complex
GO:0008024 cyclin/CDK positive transcription elongation factor complex
GO:0016604 nuclear body
GO:0016605 PML body
GO:0019908 nuclear cyclin-dependent protein kinase holoenzyme complex
GO:0032806 carboxy-terminal domain protein kinase complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:1902554 serine/threonine protein kinase complex
GO:1902911 protein kinase complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1643685: Disease
R-HSA-112387: Elongation arrest and recovery
R-HSA-167152: Formation of HIV elongation complex in the absence of HIV Tat
R-HSA-167200: Formation of HIV-1 elongation complex containing HIV-1 Tat
R-HSA-112382: Formation of RNA Pol II elongation complex
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-167169: HIV Transcription Elongation
R-HSA-167287: HIV elongation arrest and recovery
R-HSA-162909: Host Interactions of HIV factors
R-HSA-5663205: Infectious disease
R-HSA-176034: Interactions of Tat with host cellular proteins
R-HSA-162599: Late Phase of HIV Life Cycle
R-HSA-167290: Pausing and recovery of HIV elongation
R-HSA-167238: Pausing and recovery of Tat-mediated HIV elongation
R-HSA-674695: RNA Polymerase II Pre-transcription Events
R-HSA-73857: RNA Polymerase II Transcription
R-HSA-75955: RNA Polymerase II Transcription Elongation
R-HSA-6807505: RNA polymerase II transcribes snRNA genes
R-HSA-2173796: SMAD2/SMAD3
R-HSA-162582: Signal Transduction
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-6796648: TP53 Regulates Transcription of DNA Repair Genes
R-HSA-167243: Tat-mediated HIV elongation arrest and recovery
R-HSA-167246: Tat-mediated elongation of the HIV-1 transcript
R-HSA-167172: Transcription of the HIV genome
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-2173793: Transcriptional activity of SMAD2/SMAD3
Summary
SymbolCDK9
Namecyclin-dependent kinase 9
Aliases PITALRE; C-2k; TAK; CDC2L4; cyclin-dependent kinase 9 (CDC2-related kinase); CTK1; cell division cycle 2-lik ......
Chromosomal Location9q34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CDK9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCDK9
Namecyclin-dependent kinase 9
Aliases PITALRE; C-2k; TAK; CDC2L4; cyclin-dependent kinase 9 (CDC2-related kinase); CTK1; cell division cycle 2-lik ......
Chromosomal Location9q34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CDK9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCDK9
Namecyclin-dependent kinase 9
Aliases PITALRE; C-2k; TAK; CDC2L4; cyclin-dependent kinase 9 (CDC2-related kinase); CTK1; cell division cycle 2-lik ......
Chromosomal Location9q34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CDK9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0450.81
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1940.924
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0640.966
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2340.452
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0930.961
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4210.874
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2160.537
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2970.832
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1160.941
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1050.945
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4850.829
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0530.307
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CDK9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCDK9
Namecyclin-dependent kinase 9
Aliases PITALRE; C-2k; TAK; CDC2L4; cyclin-dependent kinase 9 (CDC2-related kinase); CTK1; cell division cycle 2-lik ......
Chromosomal Location9q34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDK9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCDK9
Namecyclin-dependent kinase 9
Aliases PITALRE; C-2k; TAK; CDC2L4; cyclin-dependent kinase 9 (CDC2-related kinase); CTK1; cell division cycle 2-lik ......
Chromosomal Location9q34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDK9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDK9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCDK9
Namecyclin-dependent kinase 9
Aliases PITALRE; C-2k; TAK; CDC2L4; cyclin-dependent kinase 9 (CDC2-related kinase); CTK1; cell division cycle 2-lik ......
Chromosomal Location9q34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDK9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCDK9
Namecyclin-dependent kinase 9
Aliases PITALRE; C-2k; TAK; CDC2L4; cyclin-dependent kinase 9 (CDC2-related kinase); CTK1; cell division cycle 2-lik ......
Chromosomal Location9q34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CDK9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCDK9
Namecyclin-dependent kinase 9
Aliases PITALRE; C-2k; TAK; CDC2L4; cyclin-dependent kinase 9 (CDC2-related kinase); CTK1; cell division cycle 2-lik ......
Chromosomal Location9q34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CDK9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCDK9
Namecyclin-dependent kinase 9
Aliases PITALRE; C-2k; TAK; CDC2L4; cyclin-dependent kinase 9 (CDC2-related kinase); CTK1; cell division cycle 2-lik ......
Chromosomal Location9q34.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CDK9 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CDK9.
ID Name Drug Type Targets #Targets
DB03496AlvocidibSmall MoleculeCDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGB, PYGL, ......12
DB06195SeliciclibSmall MoleculeCDK1, CDK2, CDK7, CDK9, CSNK1E, MAPK1, MAPK37